EUCTR2020-001467-82-NL进行中（未招募）1 期
An Open-Label Study Evaluating Anti-Viral Effects of Voclosporin in SARS-CoV-2 Positive Kidney Transplant Recipients – the VOCOVID Study (COVID-19) - The VOCOVID Study
eiden University Medical Center0 个研究点目标入组 30 人开始时间: 2020年4月28日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Provide written informed consent, in accordance with EMA guidance on the management of clinical trials during COVID-19 pandemic (Version 2, 27 March 2020). If written consent by the trial participant is not possible (for example because of physical isolation due to COVID-19 infection), consent could be given orally by the trial participant (Art 2(j) of Directive 2001/20/EC) in the presence of an impartial witness. In such cases, the witness is required to sign and date the informed consent document and the Investigator is expected to record how the impartial witness was selected.
- •2. Male or female subjects with a minimum age of 18 years (or legal age of consent if <18 years) at Visit 1.
- •3. Subjects with a stable kidney transplant taking TAC and a confirmed diagnosis of SARS-CoV-2 by nuclear acid testing, with mild-to-moderate symptoms.
- •4. Women of childbearing potential must have a negative pregnancy test at baseline. Two effective forms of contraception must be used simultaneously unless abstinence is the chosen method. Subjects must use effective contraception during the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 10
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 20
排除标准
- •1. Subjects unable or unwilling to give written informed consent and/or to comply with study procedures.
- •2. Any known hypersensitivity or contraindication to CNIs, especially CsA, or components of any cyclosporine drug product.
- •3. Current or medical history of:
- •Congenital immunodeficiency.
- •Severe, known, active viral infections, excluding SARS-CoV-2, within 3 months of baseline (e.g., cytomegalovirus, hepatitis B virus, hepatitis C virus or HIV) that are deemed to interfere with study assessments or outcome according to Investigator’s judgement.
- •4. Severe symptoms resulting from SARS-CoV-2 infection requiring positive pressure ventilation at baseline.
- •5. Other major physical or psychiatric illness or major traumatic injury or any other medical condition associated with increased risk to the subject or that may affect study conduct or interfere with study assessments or outcome according to Investigator’s judgement.
- •6. Subjects who are pregnant, breast feeding or, if of childbearing potential, not using adequate contraceptive precautions.
- •7. Participation in another interventional clinical study within 4 weeks prior to baseline and/or receipt of investigational drugs within 4 weeks or 5 half-lives of the drug (whichever is longer) prior to baseline.
- •8. Subjects less than 3 months post-transplant.
- •9. Subjects with documented organ rejection within the past 3 months.
- •10. Subjects with a documented estimated glomerular filtration rate (eGFR) <15 ml/min within the previous 3 months prior to screening.
研究者
相似试验
已完成
2 期
An Open-Label Study Evaluating Anti-Viral Effects of Voclosporin in SARS-CoV-2 Positive Kidney Transplant Recipients - the VOCOVID StudyNL-OMON55051eids Universitair Medisch Centrum20
招募中
2 期
An Open-Label Study Evaluating the Antiviral Activity of Tenofovir Disoproxil Fumarate (DF) 300mg in Patients with Chronic Hepatitis B Infection and Persistent Viral Replication after Long-Term Therapy with Adefovir Dipivoxil 10mg DailyHepatitis BACTRN12606000381583Austin Health (investigator initiated)60
进行中（未招募）
1 期
Phase 1/2 study of IMC-I109V in non-cirrhotic HBeAg-negative chronic HBV infectiochronic hepatitis B virus (HBV) infectionMedDRA version: 20.0Level: LLTClassification code 10019182Term: HBVSystem Organ Class: 100000004848MedDRA version: 20.0Level: LLTClassification code 10019743Term: Hepatitis B virus (HBV)System Organ Class: 100000004848EUCTR2019-004212-64-BEImmunocore Ltd108
招募中
1 期
Phase 1/2 study of IMC-I109V in non-cirrhotic HBeAg-negative chronic hepatitis B (HBV) infectioHBeAg-negative chronic HBV infectionInfection - Other infectious diseasesOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonACTRN12620000403932Immunocore Ltd80
进行中（未招募）
1 期
Phase 1/2 study of IMC-I109V in non-cirrhotic HBeAg-negative chronic HBV infectioEUCTR2019-004212-64-PLImmunocore Ltd80